European Archives of Oto-Rhino-Laryngology

, Volume 267, Issue 9, pp 1377–1381

Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis

  • Aysenur Meric Teker
  • Arzu Yasemin Korkut
  • Volkan Kahya
  • Orhan Gedikli


This is a study evaluating the efficacy of Ankaferd Blood Stopper (ABS) as a hemostatic agent compared to hemostasis by phenylephrine in patients with anterior epistaxis. The study design is a prospective, randomized, controlled, nonblinded, clinical trial. In total, 49 patients were randomly seperated to receive hemostasis technique by means of either ABS wet tampon or phenylephrine impregnated gauze tampon for anterior epistaxis control. Patients were crossed over to the other technique after two unsuccessful attempts of the first technique. Measured outcomes such as number of applications, relationship of number of applications with bleeding intensity (1 = stains on napkin, 2 = soaked napkin, 3 = bowl needed), patient discomfort during hemostasis (0 = none, 9 = unbearable), and complications were assessed. Additional data were recorded for rebleeding within 7 days. 24 of the 49 patients were assigned to the new ABS group (group I) and remaining 25 were included in the standard phenylephrine group (group II). ABS was more effective than phenylephrine at control of anterior epistaxis (79.2 vs. 64%, p < 0.05). For the patients who crossed over from phenylephrine to ABS, 44.4% achieved hemostasis by ABS. ABS successfully treated all bleeding intensity 1 and 2 patients with one application (5 min). ABS patients experienced fewer rebleeding rates within 7 days compared to phenylephrine patients (8.3 vs. 20%, p < 0.05). The patients for which ABS was applied, significant differences in effective control of anterior epistaxis were observed compared to phenylephrine. ABS is effective, safe, quick, and easy alternative to the phenylephrine in patients with anterior epistaxis.


Epistaxis Ankaferd Blood Stopper® Hemostasis Phenylephrine 


  1. 1.
    Duncan IC, Fourie PA, le Grange CE, van der Walt HA (2004) Endovascular treatment of intractable epistaxis—results of a 4-year local audit. S Afr Med J 94:373–378PubMedGoogle Scholar
  2. 2.
    Viehweg TL, Roberson JB, Hudson JW (2006) Epistaxis: diagnosis and treatment. J Oral Maxillofac Surg 64:511–518CrossRefPubMedGoogle Scholar
  3. 3.
    Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, Firat HC (2008) Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 36:163–170PubMedGoogle Scholar
  4. 4.
    Bilgili H, Kosar A, Kurt M et al (2009) Hemostatic efficacy of Ankaferd Blood Stopper in a swine bleeding model. Med Princ Pract 18:165–169CrossRefPubMedGoogle Scholar
  5. 5.
    Bergler W, Sadick H, Gotte K, Riedel F, Hörmann K (2002) Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 111:222–228PubMedGoogle Scholar
  6. 6.
    Willems PW, Farb RI, Agid R (2009) Endovascular treatment of epistaxis. AJNR Am J Neuroradiol 30:1637–1645CrossRefPubMedGoogle Scholar
  7. 7.
    Kucik CJ, Clenney T (2005) Management of epistaxis. Am Fam Physician 71:305–311PubMedGoogle Scholar
  8. 8.
    Bhatnagar RK, Berry S (2004) Selective surgicel packing for the treatment of posterior epistaxis. Ear Nose Throat J 83:633–634PubMedGoogle Scholar
  9. 9.
    Huggins S (1969) Control of hemorrhage in otorhinolaryngologic surgery with oxidized regenerated cellulose. Eye Ear Nose Throat Mon 48:420–423PubMedGoogle Scholar
  10. 10.
    Mathiasen RA, Cruz RM (2005) Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in patients with acute anterior epistaxis. Laryngoscope 115:899–902CrossRefPubMedGoogle Scholar
  11. 11.
    Aydin S (2009) Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper. J Int Med Res 37:279PubMedGoogle Scholar
  12. 12.
    Cipil HS, Kosar A, Kaya A et al (2009) In vivo hemostatic effect of the medicinal plant extract Ankaferd Blood Stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost 15:270–276CrossRefPubMedGoogle Scholar
  13. 13.
    Kurt M, Disibeyaz S, Akdogan M, Sasmaz N, Aksu S, Haznedaroglu IC (2008) Endoscopic application of Ankaferd Blood Stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. Am J Gastroenterol 103:2156–2158CrossRefPubMedGoogle Scholar
  14. 14.
    Kurt M, Kacar S, Onal IK, Akdogan M, Haznedaroglu IC (2008) Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract. Endoscopy 40:262CrossRefGoogle Scholar
  15. 15.
    Ibis M, Kurt M, Onal IK, Haznedaroglu IC (2008) Successful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd Blood Stopper. J Altern Complement Med 14:1073–1074CrossRefPubMedGoogle Scholar
  16. 16.
    Bilgili H, Captug O, Kosar A, et al (2009) Oral systemic administration of Ankaferd Blood Stopper has no short-term toxicity in an in vivo rabbit experimental model. Clin Appl Thromb Hemost July 14 [Epub ahead of print]Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Aysenur Meric Teker
    • 1
  • Arzu Yasemin Korkut
    • 1
  • Volkan Kahya
    • 1
  • Orhan Gedikli
    • 1
  1. 1.Otorhinolaryngology DepartmentVakif Gureba Training and Research HospitalIstanbulTurkey

Personalised recommendations